The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro.
The complement system plays an important role in normal human pregnancy. Uncontrolled activation of this system has been associated with many disease states. We tested the hypothesis that the C5b-9 membrane attack complex (MAC) localizes to sites of villous injury and modulates trophoblast function. Placental sections from pregnancies with no complications, intrauterine growth restriction, or preeclampsia were immunostained and the surface density for MAC and fibrin was determined by morphometric analysis. Primary cytotrophoblasts from term placentas were cultured in a FiO(2) of <1%, 8% and 20% with 10% human serum containing active MAC or heat-inactivated control serum. Immunofluorescent MAC binding to trophoblast was quantified, and the neoepitopes formed in cytokeratin 18 filaments and poly-ADP-ribose polymerase during apoptosis were used to measure cell death. Trophoblast differentiation was assessed by HCG secretion, formation of syncytia, and expression of syncytin. MAC localized to fibrin deposits in normal placentas, and especially in placentas from IUGR and preeclampsia. MAC binding to cytotrophoblasts was inversely proportional to FiO(2) and enhanced apoptosis. MAC increased markers of differentiation in cultures at 72h (medium HCG, syncytia and syncytin expression). Our findings demonstrate that MAC associates with fibrin deposits at sites of villous injury in vivo. Hypoxia also enhances MAC deposition in cultured trophoblasts and MAC alters trophoblast function in a phenotype specific manner.
Rampersad
R
R
Department of Obstetrics and Gynecology, Washington University, 4566 Scott Avenue, Saint Louis, MO 63110, USA. rampersadr@wudosis.wustl.edu
Barton
A
A
Sadovsky
Y
Y
Nelson
D M
DM
D017209:Apoptosis / Q000502:physiology; D002824:Chorionic Villi / Q000378:metabolism* / Q000473:pathology; D015938:Complement Membrane Attack Complex / Q000378:metabolism* / Q000502:physiology; D005260:Female; D005317:Fetal Growth Retardation / Q000503:physiopathology; D005337:Fibrin / Q000378:metabolism; D006801:Humans; D010922:Placenta Diseases / Q000378:metabolism* / Q000473:pathology; D011225:Pre-Eclampsia / Q000503:physiopathology; D011247:Pregnancy; D014327:Trophoblasts / Q000378:metabolism*
D015938:Complement Membrane Attack Complex; D005337:Fibrin
Placenta. 1996 Sep;17(7):387-91
8899866
Am J Physiol Cell Physiol. 2000 May;278(5):C982-8
10794672
J Perinat Med. 2005;33(4):296-305
16207114
Placenta. 2005 Jul;26(6):439-48
15950058
Obstet Gynecol. 2002 Jan;99(1):159-67
16175681
J Biol Chem. 2002 Nov 1;277(44):41342-51
12191998
Acta Anat (Basel). 1994;150(1):55-68
7526588
Placenta. 2006 Sep-Oct;27(9-10):978-83
16376985
Am J Pathol. 2006 Aug;169(2):400-4
16877342
Autoimmunity. 2006 Aug;39(5):395-402
16923539
Placenta. 2006 Apr;27 Suppl A:S17-25
16406003
Am J Pathol. 1990 Apr;136(4):855-65
2327472
Placenta. 2003 Feb-Mar;24(2-3):219-26
12566249
J Clin Endocrinol Metab. 2005 Jul;90(7):4299-308
15840747
Am J Obstet Gynecol. 2007 Feb;196(2):167.e1-5
17306667
Mol Immunol. 2004 Jul;41(6-7):583-97
15219997
Obstet Gynecol. 1992 Jan;79(1):19-26
1727579
Clin Immunol. 2006 Feb-Mar;118(2-3):127-36
16338172
Hum Reprod. 2007 Feb;22(2):362-71
17099209
J Exp Med. 2002 Jan 21;195(2):211-20
11805148
Placenta. 2001 Aug;22(7):628-38
11504531
Science. 2000 Jan 21;287(5452):498-501
10642554
Clin Exp Immunol. 1990 May;80(2):236-40
2357851
Clin Chem. 2007 Jan;53(1):42-52
17202497
J Clin Invest. 2003 Dec;112(11):1644-54
14660741
Curr Biol. 2000 May 18;10(10):R381-3
10837212
N Engl J Med. 2001 Apr 12;344(15):1140-4
11297706
Clin Exp Immunol. 1984 Apr;56(1):175-84
6370518
Int Rev Immunol. 1993;10(1):51-64
8340677
Am J Kidney Dis. 2001 Jan;37(1):E6
11136195
Am J Pathol. 2002 Aug;161(2):449-57
12163370
Am J Pathol. 2004 Mar;164(3):1049-61
14982858
Am J Obstet Gynecol. 1999 Apr;180(4):896-902
10203658
Am J Obstet Gynecol. 1997 Jul;177(1):57-65
9240583